Corporate VCs join Hookipa's €20m series B

Two corporate investors have joined Hookipa Biotech of Austria's €20 million ($27.5 million) series B financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing, with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.

Two corporate investors have joined Hookipa Biotech of Austria's €20 million ($27.5 million) series B financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing, with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.

Hookipa has developed a replication-defective viral vector platform called Vaxwave, which can stimulate antibody and CD8+ T cell immunity. The...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category